Superstring Capital Management LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Superstring Capital Management LP reported 27 stock positions worth $111.8 million. Its top holding was Zai Lab Ltd.-ADR (ZLAB) at 13.5% of the portfolio, followed by Cytokinetics (CYTK, 10.2%) and Terns Pharmaceuticals (TERN, 10.1%). Compared with Q2 2024, it opened 8 new positions, sold out of 20, added to 7 and reduced 9. The biggest buy was a new position in Structure Therapeutics (GPCR) and the biggest sale Legend Biotech Corp.-ADR (LEGN, shares −61%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001931118
- Portfolio Value
- $111.8M (Q3 2024)
- SEC Filing
- 0001931118-24-000011 ↗ filed Nov 14, 2024
Holdings Value
Holdings 27 stocks · $111.8M
| ZLAB Zai Lab Ltd.-ADR | 13.53% | 626,932 | $15.1M | Add +191.4% |
| CYTK Cytokinetics Inc. | 10.19% | 215,798 | $11.4M | Add +15.0% |
| TERN Terns Pharmaceuticals Inc. | 10.06% | 1,348,546 | $11.2M | Add +41.0% |
| GPCR Structure Therapeutics Inc. | 8.91% | 227,047 | $10.0M | New |
| ORIC Oric Pharmaceuticals Inc. | 8.70% | 949,522 | $9.7M | New |
| TIL Instil Bio Inc. | 6.47% | 107,545 | $7.2M | New |
| NVCR Novocure Ltd. | 5.49% | 392,711 | $6.1M | Add +487.1% |
| BBIO Bridgebio Pharma Inc. | 5.16% | 226,684 | $5.8M | Add +3.1% |
| FATE Fate Therapeutics Inc. | 4.59% | 1,466,934 | $5.1M | Add +194.9% |
| CAPR Capricor Therapeutics Inc. | 4.59% | 337,347 | $5.1M | New |
| TNGX Tango Therapeutics Inc. | 4.12% | 599,048 | $4.6M | Add +418.3% |
| ETNB 89BIO Inc. | 3.94% | 595,203 | $4.4M | Reduce -12.5% |
| NKTX Nkarta Inc. | 2.99% | 740,294 | $3.3M | Reduce -15.5% |
| LEGN Legend Biotech Corp.-ADR | 2.64% | 60,515 | $2.9M | Reduce -60.9% |
| ZBIO Zenas Biopharma Inc. | 1.69% | 111,605 | $1.9M | New |
| ALLO Allogene Therapeutics Inc. | 1.20% | 478,115 | $1.3M | Reduce -30.7% |
| SYRE Spyre Therapeutics Inc. | 0.98% | 37,287 | $1.1M | Reduce -18.2% |
| SVRA Savara Inc. | 0.76% | 200,000 | $848K | No change |
| BMEA Biomea Fusion Inc. | 0.75% | 83,554 | $844K | Reduce -50.0% |
| TRML Tourmaline Bio Inc. | 0.67% | 29,104 | $748K | Reduce -69.4% |
| ZURA Zura Bio Ltd. | 0.57% | 156,626 | $636K | No change |
| CABA Cabaletta Bio Inc. | 0.56% | 131,795 | $622K | Reduce -5.8% |
| CRBP Corbus Pharmaceuticals Holdi | 0.47% | 25,401 | $524K | Reduce -55.0% |
| IMVT Immunovant Inc. | 0.32% | 12,447 | $355K | New |
| CGEM Cullinan Therapeutics Inc. | 0.31% | 20,840 | $349K | New |
| LAKESHORE BIOPHARMA CO LTD | 0.19% | 307,920 | $212K | No change |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.15% | 33,824 | $172K | New |
Options reported separately and not counted above: ZLAB calls ($2.4M).
Portfolio Sells Q2 2024 → Q3 2024
| LEGN Legend Biotech Corp.-ADR | Reduce -60.9% | 2.64% | −6.00 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −4.28 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −4.11 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −3.64 |
| NKTX Nkarta Inc. | Reduce -15.5% | 2.99% | −3.53 |
| ETNB 89BIO Inc. | Reduce -12.5% | 3.94% | −2.93 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -55.0% | 0.47% | −2.75 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −2.25 |
| PYXS Pyxis Oncology Inc. | Sold out | 0.00% | −2.02 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −1.83 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −1.77 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −1.55 |
| ALLK Allakos LLC | Sold out | 0.00% | −1.19 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −1.10 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −0.94 |
| TRML Tourmaline Bio Inc. | Reduce -69.4% | 0.67% | −0.87 |
| ALLO Allogene Therapeutics Inc. | Reduce -30.7% | 1.20% | −0.83 |
| CABA Cabaletta Bio Inc. | Reduce -5.8% | 0.56% | −0.76 |
| ATYR Atyr Pharma Inc. | Sold out | 0.00% | −0.62 |
| PEPG Pepgen Inc. | Sold out | 0.00% | −0.59 |
| KPTI Karyopharm Therapeutics Inc. | Sold out | 0.00% | −0.58 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −0.41 |
| MRNS Marinus Pharmaceuticals Inc. | Sold out | 0.00% | −0.39 |
| SYRE Spyre Therapeutics Inc. | Reduce -18.2% | 0.98% | −0.37 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.28 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −0.25 |
| SYRS Syros Pharmaceuticals Inc. | Sold out | 0.00% | −0.25 |
| BMEA Biomea Fusion Inc. | Reduce -50.0% | 0.75% | −0.19 |
| SPRB Spruce Biosciences Inc. | Sold out | 0.00% | −0.05 |
Portfolio Buys Q2 2024 → Q3 2024
| GPCR Structure Therapeutics Inc. | New | 8.91% | +8.91 |
| ZLAB Zai Lab Ltd.-ADR | Add +191.4% | 13.53% | +8.83 |
| ORIC Oric Pharmaceuticals Inc. | New | 8.70% | +8.70 |
| TIL Instil Bio Inc. | New | 6.47% | +6.47 |
| CAPR Capricor Therapeutics Inc. | New | 4.59% | +4.59 |
| NVCR Novocure Ltd. | Add +487.1% | 5.49% | +4.04 |
| TNGX Tango Therapeutics Inc. | Add +418.3% | 4.12% | +2.87 |
| FATE Fate Therapeutics Inc. | Add +194.9% | 4.59% | +2.53 |
| TERN Terns Pharmaceuticals Inc. | Add +41.0% | 10.06% | +1.85 |
| ZBIO Zenas Biopharma Inc. | New | 1.69% | +1.69 |
| IMVT Immunovant Inc. | New | 0.32% | +0.32 |
| CGEM Cullinan Therapeutics Inc. | New | 0.31% | +0.31 |
| CLYM Climb Bio Inc. | New | 0.15% | +0.15 |
| BBIO Bridgebio Pharma Inc. | Add +3.1% | 5.16% | −1.86 |
| CYTK Cytokinetics Inc. | Add +15.0% | 10.19% | −2.63 |
Options Activity Q2 2024 → Q3 2024
| ZLAB Zai Lab Ltd.-ADR | call | New | 100,000 | $2.4M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $158.4M | COGT, AXSM, GMAB, CLDX, TRVI |
| Q1 2026 | 35 | $140.0M | SMMT, IMVT, COGT, SVRA, URGN |
| Q4 2025 | 45 | $186.8M | CDTX, TERN, URGN, COGT, DVAX |
| Q3 2025 | 35 | $101.5M | ZLAB, CDTX, TERN, ETNB, IMVT |
| Q2 2025 | 35 | $80.3M | COGT, VRNA, NBIX, TERN, RARE |
| Q1 2025 | 33 | $83.8M | ZLAB, BBIO, VRNA, LEGN, PFE |
| Q4 2024 | 38 | $113.9M | ORIC, TERN, ZLAB, NVCR, BBIO |
| Q3 2024 | 27 | $111.8M | ZLAB, CYTK, TERN, GPCR, ORIC |
| Q2 2024 | 39 | $79.3M | CYTK, LEGN, TERN, BBIO, ETNB |
| Q1 2024 | 37 | $151.2M | CYTK, NKTX, ETNB, BBIO, SVRA |